Antibody Responses after a Single Dose of SARS-CoV-2 Vaccine Reported results of
immunization with SARS-CoV-2 vaccine have focused on two doses given to seronegative persons…

Antibodies with ontogenies from V H 1-2 or V H 1-46-germline genes dominate the broadly
neutralizing response against the CD4-binding site (CD4bs) on HIV-1. Here, we define with …

A preventive HIV-1 vaccine should induce HIV-1–specific broadly neutralizing antibodies (bnAbs).
However, bnAbs generally require high levels of somatic hypermutation (SHM) to …

The RV144 Thai trial HIV-1 vaccine of recombinant poxvirus (ALVAC) and recombinant HIV-1
gp120 subtype B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy. Here we …

SR proteins are a well-conserved class of RNA-binding proteins that are essential for
regulation of splice-site selection, and have also been implicated as key regulators during other …

Antibodies are the primary correlate of protection for most licensed vaccines; however, their
mechanisms of protection may vary, ranging from physical blockade to clearance via the …

Induction of broadly neutralizing antibodies (bnAbs) is a goal of HIV-1 vaccine development.
Antibody 10E8, reactive with the distal portion of the membrane-proximal external region (…

Background The global pandemic of coronavirus disease 2019 (COVID-19) is caused by
infection with the SARS-CoV-2 virus. Currently, there are three approved vaccines against …

INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has not …

Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied
the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated …